Effects of ubiquinone (coenzyme Q10) on myopathy in statin users

Current Opinion in Lipidology

Volumn 19, Issue 6, 2008, Pages 553-557

  Schaars, Carel F ^a   Stalenhoef, Anton F H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Coenzyme Q10; Hypercholesterolemia; Myopathy; Statin therapy; Ubiquinone

Indexed keywords

ALPHA TOCOPHEROL; ATORVASTATIN; MEVALONIC ACID; MEVINOLIN; PLACEBO; SIMVASTATIN; UBIQUINONE;

BRAIN DISEASE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; ELECTRON TRANSPORT; HUMAN; HYPERCHOLESTEROLEMIA; LACTIC ACIDOSIS; MELAS SYNDROME; MITOCHONDRIAL MYOPATHY; MITOCHONDRIAL RESPIRATION; MUSCLE BIOPSY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MITOCHONDRIA; MUSCULAR DISEASES; UBIQUINONE;

EID: 56549119551     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e3283168ecd     Document Type: Review

References (46)

1. Jackevicius CA, Tu JV, Ross JS, et al. Use of ezetimibe in the United States and Canada. N Engl J Med 2008; 358:1819-1828.
2. Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO study. Cardiovasc Drugs Ther 2005; 19:403-414.
3. Scott RS, Lintott CJ, Wilson MJ. Simvastatin and side effects. N Z Med J 1991; 104:493-495.
4. Evans M, Rees A. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? Drug Saf 2002; 25:649-663.
5. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006; 97:52C-60C.
6. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003; 289:1681-1690.
7. Harper CR, Jacobson TA. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr Opin Lipidol 2007; 18:401-408. This is a concise recent review on statin-associated myopathy.
8. Ghirlanda G, Oradei A, Manto A, et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol 1993; 33:226-229.
9. Folkers K, Langsjoen P, Willis R, et al. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci U S A 1990; 87:8931-8934.
10. Walravens PA, Greene C, Frerman FE. Lovastatin, isoprenes, and myopathy. Lancet 1989; 2:1097-1098.
11. Ogasahara S, Engel AG, Frens D, Mack D. Muscle coenzyme Q deficiency in familial mitochondrial encephalopathy. Proc Natl Acad Sci U S A 1989; 86:2379-2382.
12. Chariot P, Abadia R, Agnus D, et al. Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome. Am J Med 1993; 94:109-110.
13. Elmberger PG, Kalén A, Lund E, et al. Effects of pravastatin and cholestyramine on products of the mevalonate pathway in familial hypercholesterolemia. J Lipid Res 1991; 32:935-940.
14. Bargossi AM, Grossi G, Fiorella PL, et al. Exogenous CoQ10 supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors. Mol Aspects Med 1994; 15 (Suppl):s187-s193.
15. Berthold HK, Naini A, Di Mauro S, et al. Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial. Drug Saf 2006; 29:703-712.
16. Laaksonen R, Ojala JP, Tikkanen MJ, Himberg JJ. Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1994; 46:313-317.
17. Laaksonen R, Jokelainen K, Sahi T, et al. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin Pharmacol Ther 1995; 57:62-66.
18. Watts GF, Castelluccio C, Rice-Evans C, et al. Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin. J Clin Pathol 1993; 46:1055-1057.
19. Mortensen SA, Leth A, Agner E, Rohde M. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med 1997; 18 (Suppl):S137-S144.
20. Rundek T, Naini A, Sacco R, et al. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Arch Neurol 2004; 61:889-892.
21. Laaksonen R, Jokelainen K, Laakso J, et al. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol 1996; 77:851-854.
22. De Pinieux G, Chariot P, Ammi-Said M, et al. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol 1996; 42:333-337.
23. de Lorgeril M, Salen P, Bontemps L, et al. Effects of lipid-lowering drugs on left ventricular function and exercise tolerance in dyslipidemic coronary patients. J Cardiovasc Pharmacol 1999; 33:473-478.
24. Human JA, Ubbink JB, Jerling JJ, et al. The effect of Simvastatin on the plasma antioxidant concentrations in patients with hypercholesterolaemia. Clin Chim Acta 1997; 263:67-77.
25. Jula A, Marniemi J, Huupponen R, et al. Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial. JAMA 2002; 287:598-605.
26. Päivä H, Thelen KM, Van Coster R, et al. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther 2005; 78:60-68.
27. Davidson M, McKenney J, Stein E, et al. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. Am J Cardiol 1997; 79:1475-1481.
28. Thibault A, Samid D, Tompkins AC, et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 1996; 2:483-491.
29. Mabuchi H, Nohara A, Kobayashi J, et al. Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: a randomized double-blind study. Atherosclerosis 2007; 195:e182-e189. A recent article studying the effect of coenzyme Q10 supplementation on serum creatine kinase, AST and ALT levels in hypercholesterolemic patients treated with atorvastatin.
30. Young JM, Florkowski CM, Molyneux SL, et al. Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia. Am J Cardiol 2007; 100:1400-1403. A recent well conducted pilot study on coenzyme Q10 supplementation in statin-associated myopathy in patients treated with simvastatin.
31. Passi S, Stancato A, Aleo E, et al. Statins lower plasma and lymphocyte ubiquinol/ubiquinone without affecting other antioxidants and PUFA. Biofactors 2003; 18:113-124.
32. Miyake Y, Shouzu A, Nishikawa M, et al. Effect of treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on serum coenzyme Q10 in diabetic patients. Arzneimittelforschung 1999; 49:324-329.
33. Palomäki A, Malminiemi K, Metsä-Ketelä T. Enhanced oxidizability of ubiquinol and alpha-tocopherol during lovastatin treatment. FEBS Lett 1997; 410:254-258.
34. Palomäki A, Malminiemi K, Solakivi T, Malminiemi O. Ubiquinone supplementation during lovastatin treatment: effect on LDL oxidation ex vivo. J Lipid Res 1998; 39:1430-1437.
35. Caso G, Kelly P, McNurlan MA, Lawson WE. Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 2007; 99:1409-1412. Another recent pilot study on coenzyme Q10 supplementation in statin-associated myopathy. The effect of supplementation with CoQ10 is compared with vitamin E supplementation on pain severity and pain interference with daily activities.
36. Mabuchi H, Higashikata T, Kawashiri M, et al. Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atovastatin in hypercholesterolemic patients. J Atheroscler Thromb 2005; 12:111-119.
37. Silver MA, Langsjoen PH, Szabo S, et al. Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction. Am J Cardiol 2004; 94:1306-1310.
38. Bleske BE, Willis RA, Anthony M, et al. The effect of pravastatin and atorvastatin on coenzyme Q10. Am Heart J 2001; 142:E2.
39. Mabuchi H, Haba T, Tatami R, et al. Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10 levels in patients with familial hypercholesterolemia. Atheroscler Suppl 2004; 5:51-55.
40. Tomasetti M, Alleva R, Solenghi MD, Littarru GP. Distribution of antioxidants among blood components and lipoproteins: significance of lipids/CoQ10 ratio as a possible marker of increased risk for atherosclerosis. Biofactors 1999; 9:231-240.
41. Lamperti C, Naini AB, Lucchini V, et al. Muscle coenzyme Q10 level in statin-related myopathy. Arch Neurol 2005; 62:1709-1712.
42. Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002; 137:581-585.
43. Goli AK, Goli SA, Byrd RP Jr, Roy TM. Simvastatin-induced lactic acidosis: a rare adverse reaction? Clin Pharmacol Ther 2002; 72:461-464.
44. Lalani SR, Vladutiu GD, Plunkett K, et al. Isolated mitochondrial myopathy associated with muscle coenzyme Q10 deficiency. Arch Neurol 2005; 62:317-320.
45. Brown MS, Goldstein JL. Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J Lipid Res 1980; 21:505-517.
46. Anon. ClinicalTrials.gov http://www.clinicaltrials.gov. [Accessed 24 June 2008].